ReviewFrontiers in pain research (Lausanne, Switzerland)2026
Non-invasive brain stimulation for neuropathic orofacial pain: a mini-review.
Review in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic orofacial pain (NOP) can seriously affect the quality of life of patients. Due to the concentration of pain in the central area of the craniofacial region, it is not only highly invasive but also easily distracts the patient's attention, resulting in its destructive nature far exceeding that of distal limb pain. As emerging non-invasive therapies, Repetitive Transcranial Magnetic Stimulation (rTMS) and Transcranial Direct Current Stimulation (tDCS) are bringing hope for the treatment of NOP. This brief review summarizes existing evidence on their efficacy, highlighting that pain phenotype may be a key determinant of treatment response and warrants further investigation. High-frequency (10-20 Hz) rTMS over the primary motor cortex (M1) reduces trigeminal and postherpetic neuralgia pain by 30%-45%, with effects lasting weeks to months. Non-somatotopic hand M1 stimulation appears to produce comparable facial analgesia via descending pain pathways. For tDCS, preliminary evidence suggests pure paroxysmal pain may respond more robustly than persistent pain, implicating central sensitization as a potential negative predictor. Current evidence is limited by small samples and heterogeneous protocols. Future research should prioritize phenotype-stratified trials, optimal parameters, and synergy with pharmacotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.